![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/30/2920713/0/en/Anaveon-appoints-Dieter-Weinand-as-Chair-of-its-Board-of-Directors.html
https://www.globenewswire.com/news-release/2024/05/29/2889543/0/en/Anaveon-announces-IND-approval-of-ANV600-001-EXPAND-Phase-I-II-clinical-study.html
https://www.globenewswire.com/news-release/2023/03/23/2632845/0/en/Anaveon-announces-presentation-of-a-novel-development-compound-at-the-2023-American-Association-for-Cancer-Research-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/03/16/2628317/0/en/Anaveon-announces-first-patient-dosed-with-ANV419-in-a-Phase-I-II-Study-of-ANV419-in-patients-with-multiple-myeloma.html
https://www.globenewswire.com/news-release/2023/02/02/2600164/0/en/Anaveon-doses-first-patient-in-a-Phase-I-II-Study-of-ANV419-as-monotherapy-or-in-combination-with-check-point-inhibitors-in-patients-with-advanced-melanoma.html
https://www.globenewswire.com/news-release/2022/09/10/2513542/0/en/Anaveon-presents-updated-data-from-the-Phase-I-II-study-of-ANV419-during-the-ESMO-Congress-2022.html
https://www.globenewswire.com/news-release/2022/04/08/2419442/0/en/Anaveon-presents-compelling-data-from-the-Phase-I-II-study-of-ANV419-during-the-AACR-Annual-Meeting-2022.html
https://www.fiercebiotech.com/biotech/pfizer-joins-119m-round-for-novartis-backed-cytokines-biotech-anaveon-to-bankroll-phase-2